Global Cancer Immunotherapy Market Analysis and Forecast by Segment, Product Segment and Company in 2016 Report
Complete Report Title “Global & USA Cancer Immunotherapy Market Analysis to 2020” describes the evolution of such a huge market in 20 chapters supported by over 180 tables and figures in 317 pages Available at ReportsnReports.com
Pune, Maharastra -- (SBWire) -- 07/18/2016 --Global & USA Cancer Immunotherapy Market Analysis to 2020 report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for cancer patients can achieve a blockbuster status. Within cancer therapeutics, immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone.
Complete Report Title "Global & USA Cancer Immunotherapy Market Analysis to 2020" describes the evolution of such a huge market in 20 chapters supported by over 180 tables and figures in 317 pages Available @ http://www.reportsnreports.com/reports/367066-global-usa-cancer-immunotherapy-market-analysis-to-2020.html.
A comprehensive account of company product portfolios are provided for 79 Cancer Immunotherapy pharma and biotech companies including:
Amgen Inc., Biogen Idec Inc.x , Bristol-Myers Squibb Co., Cellectis, Cellerant Therapeutics Inc., Celldex Therapeutics, Eli Lilly and Co., EMD Serono Inc., Genentech Inc., Genmab AS, GlaxoSmithKline, ImmunoGen Inc., Immunomedics Inc., Janssen Biotech Inc.,Juno Therapeutics Inc.,Merck & Co., Inc., Oxford BioTherapeutics Ltd., Progenics Pharmaceuticals Inc., Roche Holdings Inc., Seattle Genetics Inc., Sorrento Therapeutics Inc., Kite Pharma,Novartis
Prior to the launching of Yervoy, the five-year survival rate for patients with early stage melanoma was 98%; but the five-year survival rate for late-stage melanoma was just 16%. Yervoy has been reported to have a survival rate of 25% when tested alone. When tested as part of a combination therapy treatment with Bristol's nivolumab, the two-year survival rates rose to 88% for patients with late-stage cancer. Increase in patient survival rates brought about by cancer immunotherapy treatment is similar to that seen when bone marrow transplantation changed our conception on how blood cancer was treated.
Therefore, it is no wonder that in 2013, most science journals hailed cancer immunotherapy as the breakthrough treatment of the year. Conceivably, what makes advancements in cancer immunotherapy research even more dramatic is the fact it has the potential to treat a wide range of tumor types. If the present trends continue, cancer immunotherapy drugs will have a market value of about $80 billion in 2020. A single drug, Bristol-Myers Squibb's Yervoy, for example has earned revenues of about $960 million in 2013 and it is expected to have a market value of $1,775.2 million in 2020.
Another area of anticancer therapy is cancer vaccines. There are two different types of cancer vaccines: prophylactic vaccines to prevent cancers from occurring, and therapeutic vaccines to treat pre-existing cancers. A few prophylactic vaccines for viral-associated cancers have had significant success, such as the human papillomavirus vaccine that helps prevent cervical cancer. On the other hand, therapeutic vaccines have proven much more elusive and a string of failures bred significant skepticism. Ultimately, in 2010, perseverance paid off and the first therapeutic vaccine sipuleucel-T for the treatment of metastatic prostate cancer was approved by the FDA: In spite of its financial restructuring efforts, Dendreon earned $303.8 million in 2014 which was $20.1 million more than its 2013 sales revenue.
Request Sample Of Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=367066
This report is presented as follows:
The global market for cancer immunotherapy by the following sub-categories are presented:
By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)
By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors)
By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)
Table of Contents
Cancer Immunotherapy: An Overview
Current Status of Cancer Immunotherapy: An Overview
Challenges in Cancer Medicine Research: An Overview
Cancer Immunotherapeutic Products: An Overview
Available Immunotherapies for Cancer by Disease Type: An Overview
Cancer Incidence and Mortality: An Overview
Market for Cancer Immunotherapy
Cancer Immunotherapy Market Participants by Product Segment
CAR T Therapy
Regulations Pertaining to Immunotherapy Regulation in the USA
Regulations for Immunotherapy in Japan
European Regulation and Immunotherapeutics
Pricing & Cost Analysis
Purchase a Single User Copy For US $3760 @ http://www.reportsnreports.com/purchase.aspx?name=367066 OR Inquire for Discount on Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=367066.
List of Tables
Table 2.1: Types of Immune Cells and their Functions
Table 2.2: FDA-Approved Cancer Immunotherapies, 1986-2014
Table 2.3: FDA-Approved Monoclonal Antibodies (MAbs) to Treat Cancer
Table 2.4: Most Frequently Targeted Antigens by MAbs
Table 2.5: FDA-Approved Monoclonal Antibodies
Table 2.6: Cytotoxic Wareheads Used in ADCs
Table 2.7: Targeted Indications for ADCs
Table 2.8: Antibody Drug Conjugates: Developmental Tmeline
Table 2.9: Target Antigens for ADCs in Preclinical and Clinical Development
Table 2.10: Current ADCs Launched, Withdrawn and in Phase I/II/III Trials by Sponsor, Indication, Antigen, Cytotoxin and Linker
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Media Relations Contact
View this press release online at: http://rwire.com/707167